Hua Yuan Securities has issued a research report forecasting that HUTCHMED's (00013) total revenue for 2026-2028 will reach USD 632 million, USD 771 million, and USD 890 million, respectively. Based on a DCF valuation with a perpetual growth rate of 2% and a WACC of 7.84%, the firm calculates a reasonable equity value of HKD 27 billion for the company (using an exchange rate of USD 1 = HKD 7.82). The report notes the company's steady progress in overseas commercialization and the promising potential of its ATTC platform pipeline, leading to the maintenance of a "Buy" rating. The main points from Hua Yuan Securities are as follows:
On March 5, 2026, HUTCHMED announced its full-year 2025 results. Total operating revenue for 2025 was USD 549 million, representing a year-on-year decrease of 12.96%. However, net profit attributable to the company was USD 457 million, reflecting a significant year-on-year increase of 1111.03%.
The company demonstrates sustainable growth in its global commercialization efforts and maintains a solid financial position. Revenue from its Oncology/Immunology business reached USD 286 million, which included USD 71 million from upfront and milestone payments. By market, sales outside of China amounted to USD 366 million, a 26% year-on-year increase, with second-half 2025 sales growing 25% compared to the first half. Sales within China were USD 159 million, a 25% year-on-year decrease, though second-half 2025 sales showed a 21% increase over the first half. By product: 1) Fruquintinib overseas sales grew 26% to USD 366.2 million, benefiting from successful product launches and expanded insurance coverage; 2) Fruquintinib sales in the domestic market were USD 100.1 million, with strong growth in the second half; 3) Savolitinib secured its third lung cancer indication approval in China, triggering a USD 11 million milestone payment from AstraZeneca. The company holds a substantial cash balance of USD 1.367 billion. The revenue guidance for the Oncology/Immunology business in 2026 is between USD 330 million and USD 450 million. Overall, the company's global commercialization progress is sustainable, and its financial condition is robust.
The ATTC platform pipeline is progressively entering the clinical validation stage. 1) HMPL-A251: Following the presentation of preclinical data at the AACR-NCI-EORTC conference in October 2025, the first clinical trial for the initial ATTC candidate, HMPL-A251, was initiated in December 2025. 2) The clinical trial for HMPL-A580 commenced in March 2026. 3) HMPL-A830 is planned to enter Phase I clinical trials by the end of the year. The company is actively exploring potential opportunities for collaboration with multinational pharmaceutical companies to co-develop related ATTC candidates, indicating a promising future.
The pipeline offers a rich set of future catalysts. 1) Savolitinib: Announcement of global SAFFRON data, announcement of Chinese SANOVO data, and NDA approval in China for third-line gastric cancer. 2) Sovleplenib: Approval in China for the ITP indication and submission in China for wAIHA. 3) ATTC Platform: Presentation of preclinical data for A580, submission of INDs in China and the US for A830, and initiation of global clinical studies. 4) Fruquintinib: Approval in China for the RCC indication. 5) Surufatinib: Completion of patient enrollment for the Phase 3 PDAC study. 6) HMPL-453: NDA approval for IHCC.
Risk factors include potential failure in clinical development, a worsening competitive landscape, and sales performance falling short of expectations.
Comments